|
Insmed is on a development path to discover drugs for neurological, muscular, and metabolic ailments. Its protein program is clinically focused on the development of lead candidate IPLEX as a potential treatment for conditions including muscular dystrophy, ALS (a neurodegenerative condition known as Lou Gehrig's disease), HARS (fat misdistribution associated with HIV), and retinopathy (abnormal growth of blood vessels in the retina). The company also has a preclinical research program for an oncology drug pipeline targeting breast, prostate, and colon cancer, among others.
|
| | | Contact Information | |
Address: |
8720 Stony Point Pkwy.
Richmond, VA 23235
| | Phone: | 804-565-3000 | | Fax: | 804-565-3500 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 11.70 M | | Revenue Growth (1 yr): | 55.40% | | Employees (2008): | 97 | | Employee Growth (1 yr): | 3.20% |
|
|
Key People
| | • |
Chairman:
Melvin Sharoky
| | • |
EVP and CFO:
Kevin P. Tully
| | • |
Chief Business Officer:
Stephen C. (Steve) Glover
|
|
|
